4.5 Article

Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort

期刊

NEUROBIOLOGY OF AGING
卷 31, 期 8, 页码 1355-1363

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2010.04.031

关键词

ADNI; Alzheimer's disease; Mitochondrial polymorphism; Mitochondrial haplogroups

资金

  1. Pfizer Inc.
  2. Wyeth Research
  3. Bristol-Myers Squibb
  4. Eli Lilly and Company
  5. GlaxoSmithKline
  6. Merck Co. Inc.
  7. AstraZeneca

向作者/读者索取更多资源

Despite the central role of amyloid deposition in the development of Alzheimer's disease (AD), the pathogenesis of AD still remains elusive at the molecular level. Increasing evidence suggests that compromised mitochondrial function contributes to the aging process and thus may increase the risk of AD. Dysfunctional mitochondria contribute to reactive oxygen species (ROS) which can lead to extensive macromolecule oxidative damage and the progression of amyloid pathology. Oxidative stress and amyloid toxicity leave neurons chemically vulnerable. Because the brain relies on aerobic metabolism, it is apparent that mitochondria are critical for the cerebral function. Mitochondrial DNA sequence changes could shift cell dynamics and facilitate neuronal vulnerability. Therefore we postulated that mitochondrial DNA sequence polymorphisms may increase the risk of AD. We evaluated the role of mitochondrial haplogroups derived from 138 mitochondrial polymorphisms in 358 Caucasian Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Our results indicate that the mitochondrial haplogroup UK may confer genetic susceptibility to AD independently of the apolipoprotein E4 (APOE4) allele. Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据